Home » Topics » Regulatory » EMA

EMA
RSS

European orphan drug status for Celldex Therapeutics' rindopepimut

Nov. 2, 2011

Amsterdam Molecular Therapeutics announces restructuring

Oct. 31, 2011

Lilly withdraws Xigris worldwide following PROWESS-SHOCK study

Oct. 26, 2011

EMA begins new review of Protelos and Osseor

Oct. 26, 2011

CHMP issues opinion on approval of Bronchitol

Oct. 25, 2011

CHMP maintains earlier opinion after reexamining Glybera MAA

Oct. 25, 2011

CHMP clarifies opinion on pioglitazone and the risk of bladder cancer

Oct. 24, 2011

EMA finds no link between cancer and use of angiotensin AT receptor antagonists

Oct. 21, 2011

Thrombogenics' ocriplasmin MAA accepted for review

Oct. 21, 2011

Isotechnika receives scientific advice from EMA for voclosporin trial

Oct. 19, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 21, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...